| 3.74 -0.02 (-0.53%) | 02-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.76  |
1-year : | 5.11 |
| Resists | First : | 4.07 |
Second : | 4.37 |
| Pivot price | 3.9 |
|||
| Supports | First : | 3.59 | Second : | 2.99 |
| MAs | MA(5) : | 3.78  |
MA(20) : | 3.89 |
| MA(100) : | 4.57 |
MA(250) : | 4.39 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 16 |
D(3) : | 21.2 |
| RSI | RSI(14): 37.8 |
|||
| 52-week | High : | 7.07 | Low : | 2.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ORGO ] has closed above bottom band by 19.1%. Bollinger Bands are 62.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.8 - 3.82 | 3.82 - 3.84 |
| Low: | 3.63 - 3.66 | 3.66 - 3.68 |
| Close: | 3.7 - 3.74 | 3.74 - 3.77 |
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Sun, 25 Jan 2026
The Truth About Organogenesis Holdings (ORGO): Quiet Biotech Sleeper Stock or Total Trap? - AD HOC NEWS
Thu, 22 Jan 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO - Sahm
Sat, 17 Jan 2026
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28% - simplywall.st
Sun, 11 Jan 2026
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth? - simplywall.st
Mon, 15 Dec 2025
Organogenesis stock soars after FDA meeting clears path for ReNu BLA - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 127 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 46.6 (%) |
| Held by Institutions | 55 (%) |
| Shares Short | 12,890 (K) |
| Shares Short P.Month | 11,270 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | 0.2 % |
| Operating Margin | 14.6 % |
| Return on Assets (ttm) | 0.1 % |
| Return on Equity (ttm) | 0.3 % |
| Qtrly Rev. Growth | 31 % |
| Gross Profit (p.s.) | 2.73 |
| Sales Per Share | 3.66 |
| EBITDA (p.s.) | 0.15 |
| Qtrly Earnings Growth | 22.2 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -46.75 |
| PEG Ratio | 0 |
| Price to Book value | 1.86 |
| Price to Sales | 1.02 |
| Price to Cash Flow | -12.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|